tenidap tenidap tenidap was a cox/5-lox inhibitor and cytokine-modulating anti-inflammatory drug candidate that was under development by pfizer as a promising potential treatment for rheumatoid arthritis, but pfizer halted development after marketing approval was rejected by the fda in 1996 due to liver and kidney toxicity, which was attributed to metabolites of the drug with a thiophene moiety that caused oxidative damage. tenidapclinical dataatc codem01ax23 (who) identifiers iupac name 5-chloro-2-hydroxy-3-(2-thienylcarbonyl)-1h-indole-1-carboxamide cas number120210-48-2 ypubchem cid60712chemspider54717 nunii9k7cj74onhkeggd06072 ychemblchembl1097558 ncomptox dashboard (epa)dtxsid9046104 chemical and physical dataformulac14h9cln2o3smolar mass320.75 g·mol−13d model (jsmol)interactive image smiles c1cc(sc1)c(=o)c2c3cc(ccc3n(c2o)c(=o)n)cl inchi inchi=1s/c14h9cln2o3s/c15-7-3-4-9-8(6-7)11(13(19)17(9)14(16)20)12(18)10-2-1-5-21-10/h1-6,19h,(h2,16,20) nkey:izsfdumvcvvwkw-uhfffaoysa-n n ny (what is this?) (verify)